Immunity, Inflammation and Disease (Jul 2024)
Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS‐CoV‐2 neutralization
Abstract
Abstract Background SARS‐CoV2 virus, responsible for the COVID‐19 pandemic, has four structural proteins and 16 nonstructural proteins. S‐protein is one of the structural proteins exposed on the virus surface and is the main target for producing neutralizing antibodies and vaccines. The S‐protein forms a trimer that can bind the angiotensin‐converting enzyme 2 (ACE2) through its receptor binding domain (RBD) for cell entry. Aims The goal of this study was to express in HEK293 cells a new RBD recombinant protein in a constitutive and stable manner in order to use it as an alternative immunogen and diagnostic tool for COVID‐19. Materials & Methods The protein was designed to contain an immunoglobulin signal sequence, an explanded C‐terminal section of the RBD, a region responsible for the bacteriophage T4 trimerization inducer, and six histidines in the pCDNA‐3.1 plasmid. Following transformation, the cells were selected with geneticin‐G418 and purified from serum‐fre culture supernatants using Ni2+‐agarand size exclusion chromatography. The protein was structurally identified by cross‐linking and circular dichroism experiments, and utilized to immunize mice in conjuction with AS03 or alum adjuvants. The mice sera were examined for antibody recognition, receptor‐binding inhibition, and virus neutralization, while spleens were evaluated for γ‐interferon production in the presence of RBD. Results The protein released in the culture supernatant of cells, and exhibited a molecular mass of 135 kDa with a secondary structure like the monomeric and trimeric RBD. After purification, it formed a multimeric structure comprising trimers and hexamers, which were able to bind the ACE2 receptor. It generated high antibody titers in mice when combined with AS03 adjuvant (up to 1:50,000). The sera were capable of inhibiting binding of biotin‐labeled ACE2 to the virus S1 subunit and could neutralize the entry of the Wuhan virus strain into cells at dilutions up to 1:2000. It produced specific IFN‐γ producing cells in immunized mouse splenocytes. Discussion Our data describe a new RBD containing protein, forming trimers and hexamers, which are able to induce a protective humoral and cellular response against SARS‐CoV2. Conclusion These results add a new arsenal to combat COVID‐19, as an alternative immunogen or antigen for diagnosis.
Keywords
